Browsing by Author "Atike Pinar Erdogan"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    The Value of Inflammatory Prognostic Index in Older Patients with Hormone Receptor Positive Metastatic Breast Cancer
    (2021) Atike Pinar Erdogan; Ferhat Ekinci; Ahmet Ozveren; Senem Yilmaz; Mustafa Sahin; Bilgin Demir; Esin Oktay; Ahmet Dirican
    Objectives: To search the prognostic value of an inflammation based prognostic score in older patients with hormone positive, Her2 negative metastatic breast cancer. Methods: A retrospective study of 82 female patients aged 65 years and older with hormon receptor positive, Her-2 negative metastatic breast cancer diagnosed between 2011 and 2018 was conducted with collection of clinical and laboratory data. The inflammatory prognostic index (IPI) was calculated as C-reactive protein × NLR (neutrophil/ lym- phocyte ratio)/serum albumin. Survival estimates were calculated with Kaplan-Meier method. Results: The optimal cut-off points of IPI for the stratification of OS was found to be 0,75. Based on this cutoff value, patients were categorized as IPI-high and IPI-low group. High IPI was significantly associated with advanced stage at diagnosis. (p=0.03) The mean OS was 64 months in the IPI-high group and 66.9 months in the IPI-low group. (p=0,813) In patients receiving hormonotherapy in first line treatment PFS was 34.6 months in the IPI-low group and 14.5 months in the IPI high group, and a statistically significant difference was found compared to patients who received chemo- therapy in the first line. (p=0,042). Conclusion: Measurement of systemic inflammatory response in older adults with metastatic breast cancer is reliable, available, and can be clinically incorporated into current geriatric oncology algorithms
  • No Thumbnail Available
    Item
    Options in First Line Management of Metastatic Pancreatic Cancer and the Determinative Role of ECOG Performance Status
    (2021) Ferhat Ekinci; Atike Pinar Erdogan; Serkan Yildirim; Ahmet Ozveren
    Objectives: It will contribute to the fact that the first-line treatment options of patients with metastatic pancreatic can- cer (PC) who apply to the oncology clinic are discussed in the light of the literature and guide the clinicians in making the initial treatment decision. Methods: Patients who were diagnosed with PC in a total of 2 centers between 2010 and 2019 and who were found to have distant organ metastases at the time of diagnosis or during follow-up were included. Patients were categorized into 3 groups in terms of metastatic first line treatments: gemcitabine (Gm), gemcitabine-platinum (cisplatin or carbo- platin) (GP) combination and FOLFIRINOX (FX). These three treatment groups were compared in terms of patient with tumor characteristics and progression free survival (PFS) - overall survival (OS). Results: The present study included 355 patients who were admitted to our clinic. The first line therapies received by the patients were analyzed, it was seen that 124 (34.9%) patients received Gm chemotherapy (CT), 43 (12.1%) pa- tients received FX, 138 (38.9%) patients received GP and 18 (5.1%) patients received other regimens. While PFS was 6.1 months in GP areas, it was the shortest with 4.4 months in Gm and the longest with 7.1 months in FX. This difference between the groups was found to be statistically significant (p<0.001). When the data were analyzed in terms of OS; the Gm arm was found to have the shortest OS with 9.6 months. However, GP attracted attention as the treatment that prolonged the OS the most with 15.4 months. This period was calculated as 13.5 months in the FX arm. Again, this dif- ference was found to be statistically significant (p<0.001). Conclusion: The main theme of our study was that ‘Eastern Cooperative Oncology Group’ performance status (ECOG PS) and age were the most important factors in decision making for the management of these patients. As age pro- gresses and PS deteriorates, clinicians move away from the FX regimen. Another important point was that the GP regi- men was preferred instead of GnP, probably due to the difficulty in drug supply in our country, and it was found to be superior to other regimens.